Innovative plant metabolites developed for OTC nasal sprays to target pathogenic bacteria in the nasal microbiome, enhancing respiratory health. These compounds provide cytoprotection and antimicrobial effects, aiming to prevent infections and improve respiratory function.
This novel class of plant-derived agents is designed to support nasal and respiratory health by targeting pathogenic bacteria associated with the nasal microbiome. These over-the-counter (OTC) products are formulated as nasal sprays that aim to prevent respiratory tract infections and enhance overall respiratory function. The compounds offer dual benefits: cytoprotection of mammalian cells and antimicrobial activity.
Key features include:
The development of these plant-derived agents has reached Technology Readiness Level 6, indicating that the product has been demonstrated in a relevant environment. Next steps include scaling up production, obtaining FDA approval, and launching the product into the market.
Medical University – Plovdiv is an internationally oriented public medical university with approximately 6,200 students and a broad clinical education and research profile. Its industry-facing model is built around affiliated university hospitals, giving researchers access to clinical environments, diagnostic and therapeutic infrastructure, and routes for evaluating innovations in practice. A large medical simulation training center, research and innovation centers, nearly 70 doctoral programs, and project-support structures facilitate collaboration with healthcare providers, life-science companies, and external research partners. Research is supported by competitive Bulgarian funding, including the Bulgarian National Science Fund and the Ministry of Education and Science, alongside European Union programs.